Date: 2017-08-31
Type of information: Resignation
Compound: chief medical officer
Company: Nabriva Therapeutics (Ireland)
Therapeutic area: Infectious diseases
Type agreement: resignation
Action mechanism:
Disease:
Details:
- • On August 31, 2017, Nabriva Therapeutics announced that Elyse Seltzer has decided to resign from her position as chief medical officer effective as of September 30, 2017 to pursue other professional endeavors. In the interim, Dr. Colin Broom, chief executive officer, will also assume the role of chief medical officer.
- Dr. Seltzer has agreed to continue to serve as a consultant to the company through the end of the first quarter of 2018 and will provide input as required as the company prepares to un-blind and analyze data from the company’s first pivotal Phase 3 clinical trial of lefamulin, LEAP 1. The company expects to announce top-line data from LEAP 1 in September 2017. The company’s second pivotal Phase 3 trial of lefamulin, LEAP 2, is on track to complete enrollment in the fourth quarter of 2017, with availability of top-line data anticipated in the first quarter of 2018.
Financial terms:
Latest news:
Is general: Yes
